Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

mber 31, 2012 was $46.2 million, or $0.66 and $0.62 income per basic and diluted earnings per share, respectively, compared to non-GAAP net income of $58.6 million, or $0.85 and $0.82 income per basic and diluted earnings per share, respectively for the quarter ended December 31, 2011.

Revenue for the six months ended December 31, 2012 was $160.7 million compared to $77.9 million for the six months ended December 31, 2011. Revenue for the quarter ended December 31, 2012 was $58.0 million compared to $77.9 million for the quarter ended December 31, 2011. Revenue for the quarter ended December 31, 2012 consisted primarily of $50.0 million of milestone revenue due to the Company's achievement of one clinical milestone in connection with the Company's collaboration and license agreement (the "Agreement") with Janssen Biotech, Inc. and its affiliates ("Janssen") and $5.0 million of license revenue related to the Company's license agreement with Novo Nordisk A/S under which Novo Nordisk A/S acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483, in a restricted disease indication outside of oncology.

To date, the Company has received three milestone payments from Janssen of $50 million each, totaling $150 million, under the Agreement. The Company may receive up to an additional $675 million in development and regulatory milestone payments, however, clinical development entails risks and the Company has no assurance as to whether or when the milestone targets might be achieved.

The Agreement with Janssen includes a cost sharing arrangement for certain development activities. In general Janssen is responsible for approximately 60% of development costs and the Company is responsible for 40% of development costs. The Agreement with Janssen also provides for a $50 million annual cap of the Company's share of development costs and pre-tax commercialization losses for each calendar year. Under the Agreeme
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014 Follow us on ... young has groomed and nurtured anti-aging products and ... emphasis on appearance maintenance is benefitting the market ... protein obtained from the bacterium, Clostridium Botulinum, which ... relaxation. With cosmetic indications for botulinum toxin ranging ...
(Date:9/22/2014)... 22, 2014 FierceBiotech today announced its ... biotechnology companies of 2014. FierceBiotech editors John Carroll ... this year’s winners. Those selected are identified as ... the industry. , "It's always a lot ... Fierce 15 companies," said Carroll. "This year in particular ...
(Date:9/22/2014)... Sept. 22, 2014  Spherix Incorporated (SPEX) -- an intellectual ... intellectual property, today announced that the United States Patent & ... in the month of September that is part of a ... patent is: USRE45,121 , Application number: US 13/728,867 ... date: Dec 27, 2012 The listed inventors ...
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
Breaking Biology Technology:Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 2Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 3FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... on Thursday announced that three Wisconsin businesses would receive ... Commerce Technology Assistance Grant (TAG) and Technology Venture Fund ... , Functional Biosciences, Inc. , is a ... It will receive a $250,000 TVF loan for work ...
... ads on their round, shiny stomachs as part of "tummy ... To some, this is "desperate branding" in action. , ... spot on the list of branding failures. These projects are ... weird processes. , ,Roy Disney said, "You need branding when ...
... summer. Business slows. Indeed, in Europe, where I find myself ... animation that will last until the first of September. People ... grasp weakens. , ,Or does it? , ,After a rare ... mountain in my inbox and a to-do list that had ...
Cached Biology Technology:A final word on branding 2A final word on branding 3A final word on branding 4A final word on branding 5Leaving it all behind 2
(Date:9/21/2014)... the University of California, San Diego, have developed a ... control the activity of genes based on sequences of ... its application to human embryonic cells in a paper ... , "All of our cells have the same blueprint, ... John Whitaker, lead author of the report. "Skin cells ...
(Date:9/21/2014)... -- Shellfish such as mussels and barnacles secrete very ... ship hulls, even underwater. Inspired by these natural adhesives, ... that could be used to repair ships or help ... new waterproof adhesives, the MIT researchers engineered bacteria to ... proteins as well as a bacterial protein found in ...
(Date:9/19/2014)... today by researchers from several Harvard University labs ... experienced and aspiring researchers with the intellectual raw ... made from soft, flexible materials. , With the ... other advances in manufacturing technology, soft robotics is ... drawn from conventional rigid robot design, but working ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2Engineered proteins stick like glue -- even in water 2Engineered proteins stick like glue -- even in water 3Soft robotics 'toolkit' features everything a robot-maker needs 2
... Not only land birds, but also some seabirds, ... example, circumnavigates the earth one and a half times ... about the migratory behaviour of seabirds as compared with ... Planck Institute for Ornithology have studied the migratory behaviour ...
... In a paradigm changing discovery, Plasmodium vivax ( ... historically thought to be resistant to the disease, those who ... red blood cells, according to researchers from Case Western Reserve ... of Health. In a study of more than 600 individuals ...
... experimental oral drug has lowered blood sugar levels and inflammation ... could someday be added to the arsenal of drugs used ... research. The drug consists of a synthetic molecule that ... inhibitory factor, or MIF. This protein is implicated in a ...
Cached Biology News:To the Antarctic or Brazil for new feathers 2To the Antarctic or Brazil for new feathers 3Duffy-negative blood types no longer protected from P. Vivax malaria 2Duffy-negative blood types no longer protected from P. Vivax malaria 3Study points to potential new drug for type 2 diabetes 2Study points to potential new drug for type 2 diabetes 3Study points to potential new drug for type 2 diabetes 4
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... Stand-96 is designed for paramagnetic bead precipitation ... ml PCR plates with no additional accessories. ... in a standard SBS 96-well microplate footprint. ... magnets guarantees easy and fast (as little ...
... circular clear acrylic chamber for complete visibility ... features microprocessor operation for precise mixing capability. ... Carousel rotates at 11 rpm; manufactured ... , Bottle Capacity - four 35 ...
Biology Products: